Steroid Injection in De Quervain Tenosynovitis

• Sponsor: National University Hospital, Singapore (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05261737
• Collaborator: (none)
• Enrollment: 50
• Location: 1
• Anticipated Duration (Months): 44.6
• Patients Per Site Per Month: 1.1

Study Details

Study Description

Brief Summary

This study is carried out to find out the degree of pain relief achieved with standard treatment as steroid injection as well as its time to onset. It will recruit 50 subjects over a period of 18 months.

Condition or Disease	Intervention/Treatment	Phase
De Quervain Disease	Procedure: Corticosteroid Injection

Detailed Description

The aim of the study is determine how effective these injections are and when will the patient start feeling relief of his/her symptoms.The aim of the study is not to change the current practice, but provide hand surgeons enough data to clarify their patients the expected outcomes and onset timing of the treatment performed.

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 50 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: Effectiveness of Steroid Injection in Treating Pain in De Quervain Tenosynovitis
• Actual Study Start Date: Mar 14, 2019
• Anticipated Primary Completion Date: Dec 1, 2022
• Anticipated Study Completion Date: Dec 1, 2022

Outcome Measures

Primary Outcome Measures

1. Determine efficacy of steroid injection [7 days]

   a single steroid injection over first dorsal compartment for patients diagnosed with de Quervain tenosynovitis will make effect within 7 days from injection, relieving pain to less or equal than 1 in Visual Analogue Scale (VAS)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 21 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• 21 years old

Exclusion Criteria:

• Pregnancy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National University Hospital	Singapore		Singapore	119074

Sponsors and Collaborators

• National University Hospital, Singapore

Investigators

• Principal Investigator: Renita Sirisena, National University Hospital, Singapore

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: National University Hospital, Singapore
• ClinicalTrials.gov Identifier: NCT05261737
• Other Study ID Numbers: 2018/00787
• First Posted: Mar 2, 2022
• Last Update Posted: Mar 2, 2022
• Last Verified: Feb 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Tenosynovitis; De Quervain Disease

Study Results

No Results Posted as of Mar 2, 2022